Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism by Mannstadt, Michael et al.
J Clin Endocrinol Metab. 2019 Nov; 104(11): 5136–5147.
Published online 2019 Aug 1.
doi: 10.1210/jc.2019-01010: 10.1210/jc.2019-01010
PMCID: PMC6760337
PMID: 31369089
Safety and Efficacy of 5 Years of Treatment With Recombinant Human
Parathyroid Hormone in Adults With Hypoparathyroidism
Michael Mannstadt, Bart L Clarke, John P Bilezikian, Henry Bone, Douglas Denham, Michael A Levine,
Munro Peacock, Jeffrey Rothman, Dolores M Shoback, Mark L Warren, Nelson B Watts, Hak-Myung Lee,
Nicole Sherry,  and Tamara J Vokes
 Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota
 Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York
 Michigan Bone and Mineral Clinic, PC, Detroit, Michigan
 Clinical Trials of Texas, Inc., San Antonio, Texas
 Division of Endocrinology and Diabetes and Center for Bone Health, Children’s Hospital of Philadelphia,
Philadelphia, Pennsylvania
 Department of Medicine, Division of Endocrinology, Indiana University School of Medicine, Indianapolis, Indiana
 University Physicians Group – Research Division, Staten Island, New York
 Endocrine Research Unit, Department of Medicine, San Francisco Veterans Affairs Medical Center, University of
California, San Francisco, California
 Endocrinology and Metabolism, Physicians East, Greenville, North Carolina
 Osteoporosis and Bone Health Services, Mercy Health, Cincinnati, Ohio
 Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies, Lexington, Massachusetts
 Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies, Cambridge, Massachusetts
 Section of Endocrinology, University of Chicago Medicine, Chicago, Illinois
Correspondence and Reprint Requests: Michael Mannstadt, MD, Endocrine Unit, Massachusetts General
Hospital and Harvard Medical School, 50 Blossom Street, Thier-1123, Boston, Massachusetts 02114. E-mail:
ude.dravrah.hgm@tdatsnnam .
Received 2019 Apr 30; Accepted 2019 Jul 26.
Copyright © 2019 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution License (CC BY;
https://creativecommons.org/licenses/by/4.0/).
Abstract
Context
Conventional hypoparathyroidism treatment with oral calcium and active vitamin D is aimed at correcting
hypocalcemia but does not address other physiologic defects caused by PTH deficiency.
Objective
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To evaluate long-term safety and tolerability of recombinant human PTH (1-84) [rhPTH(1-84)].
Design
Open-label extension study; 5-year interim analysis.
Setting
12 US centers.
Patients
Adults (N = 49) with chronic hypoparathyroidism.
Intervention(s)
rhPTH(1-84) 25 or 50 µg/d initially, with 25-µg adjustments permitted to a 100 µg/d maximum.
Main Outcome Measure(s)
Safety parameters; composite efficacy outcome was the proportion of patients with ≥50% reduction in oral
calcium (or ≤500 mg/d) and calcitriol (or ≤0.25 µg/d) doses, and albumin-corrected serum calcium
normalized or maintained compared with baseline, not exceeding upper limit of normal.
Results
Forty patients completed 60 months of treatment. Mean albumin-corrected serum calcium levels remained
between 8.2 and 8.7 mg/dL. Between baseline and month 60, levels ± SD of urinary calcium, serum
phosphorus, and calcium-phosphorus product decreased by 101.2 ± 236.24 mg/24 hours, 1.0 ± 0.78 mg/dL,
and 8.5 ± 8.29 mg /dL , respectively. Serum creatinine level and estimated glomerular filtration rate were
unchanged. Treatment-emergent adverse events (AEs) were reported in 48 patients (98.0%; hypocalcemia,
36.7%; muscle spasms, 32.7%; paresthesia, 30.6%; sinusitis, 30.6%; nausea, 30.6%) and serious AEs in 13
(26.5%). At month 60, 28 patients (70.0%) achieved the composite efficacy outcome. Bone turnover
markers increased, peaked at 12 months, and then declined to values that remained above baseline.
Conclusion
Treatment with rhPTH(1-84) for 5 years demonstrated a safety profile consistent with previous studies and
improved key biochemical parameters.
PTH plays a central role in mineral homeostasis by stimulating renal reabsorption of calcium, promoting
renal phosphate excretion, and stimulating conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D
(1,25[OH] D), the fully active form of vitamin D. Moreover, 1,25[OH] D enhances absorption of calcium
and phosphate from the gastrointestinal tract (1). In addition, PTH is a potent regulator of bone turnover
(i.e., the coupled process of bone resorption and bone formation) (2–4); deficiency of PTH results in
decreased bone turnover (2, 4). Conventional therapy for hypoparathyroidism includes oral calcium and
active vitamin D (e.g., calcitriol), as well as thiazide diuretics and magnesium supplementation as needed.
Although this approach can correct the hypocalcemia associated with hypoparathyroidism, it does not
replace other functions of PTH and can lead to or worsen hypercalciuria (2, 5). Other concerns with
conventional therapy include unpredictable episodes of hypocalcemia and hypercalcemia; increased serum
calcium-phosphorus (Ca × P) product; and complications such as extraskeletal calcifications,
nephrolithiasis, nephrocalcinosis, and decreased kidney function (2, 5–7). Reduced quality of life and
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symptoms of hypocalcemia are consistent findings among patients with hypoparathyroidism receiving
conventional treatment (8–13).
Recombinant human PTH [rhPTH(1-84)] is full-length PTH that is approved in the United States and
Europe as an adjunctive treatment of adults with hypoparathyroidism (14, 15). Safety and efficacy of
rhPTH(1-84) in patients with hypoparathyroidism have been demonstrated in short-term, placebo-
controlled and open-label studies (16–20). In the pivotal REPLACE (Use of NPSP558 in the Treatment of
Hypoparathyroidism) Study, a 24-week, double-blind, placebo-controlled, randomized phase 3 study
conducted with 134 patients, 53% of patients receiving rhPTH(1-84) vs 2% of patients receiving placebo
met the primary study end point (≥50% reduction from baseline in oral calcium and calcitriol doses with
maintenance of normal albumin-corrected serum calcium) (17). In addition, patients receiving rhPTH(1-84)
in REPLACE showed significant reductions in serum phosphorus throughout the 24-week study compared
with patients receiving placebo (21). In both study groups, urinary calcium excretion declined from
baseline, but at week 24 in both groups, the mean urinary calcium excretion remained above the upper limit
of normal (ULN) for women and near the ULN for men (17, 21).
RACE (Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human
Parathyroid Hormone [rhPTH(1-84)], for the Treatment of Adults With Hypoparathyroidism—A Clinical
Extension Study; ClinicalTrials.gov identifier, NCT01297309) was an open-label extension study designed
to assess long-term safety and efficacy of rhPTH(1-84) in patients with hypoparathyroidism. This article
reports 5-year safety and efficacy of treatment with rhPTH(1-84) and examines changes in mineral
homeostasis, kidney function, and skeletal parameters.
Materials and Methods
Study design and patients
RACE was an open-label extension conducted at 12 centers in the United States. The primary objective
was to assess long-term safety and tolerability of rhPTH(1-84) in adult patients with hypoparathyroidism (
Fig. 1). Patients were eligible to participate in RACE if they completed the randomized, placebo-controlled,
24-week REPLACE Study and/or the 8-week open-label, dose-blind RELAY (Study of Safety and Efficacy
of rhPTH[1-84] of Fixed Doses of 25 and 50 μg in Adults With Hypoparathyroidism) Study. A treatment
interruption between the end of treatment in REPLACE or RELAY and enrollment in RACE was
permitted. Additional eligibility criteria included serum creatinine level <1.5 mg/dL (<132.6 µmol/L) at
enrollment, total serum calcium level at or below the ULN based on local laboratory result before
enrollment, and serum 25(OH)D ≤1.5 times the ULN (100 ng/mL) within 16 weeks before enrollment.
Patients were permitted to continue taking most baseline concomitant medications during the trial,
including thiazide diuretics, hormone therapy (estrogen with or without progesterone), and
antihypertensives. Other drugs known to affect bone or mineral metabolism were prohibited (e.g.,
calcitonin, cinacalcet, raloxifene, bisphosphonates, fluoride).
Investigators were permitted to introduce thiazide diuretics for control of hypercalciuria at or after week 16
for patients who were on a stable dose of rhPTH(1-84), had a 24-hour urine calcium level of >300 mg (>7.5
mmol) for men or >250 mg (>6.25 mmol) for women, and had not been receiving diuretics before the start
of the study. Investigators administered sufficient supplemental cholecalciferol and/or ergocalciferol during
the study to maintain patients’ serum 25(OH)D levels between 30 and 100 ng/mL.
Patients self-administered rhPTH(1-84) subcutaneously, once daily, in the morning. For this study, a
starting dose of 50 µg/d was used for patients with a total serum calcium concentration ≤9.5 mg/dL (≤2.37
mmol/L) and for patients with a serum calcium concentration >9.5 mg/dL who were taking ≥500 mg of
calcium and/or any calcitriol. A starting dose of 25 µg/d was used for patients with a total serum calcium
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concentration >9.5 mg/dL who were taking <500 mg of supplemental calcium and no calcitriol. The dose
of rhPTH(1-84) could be increased or decreased by the investigator in stepwise increments of 25 µg up to a
maximum dose of 100 µg/d any time during the study, with the goal of achieving or maintaining total
serum calcium levels in the target range of 8.0 to 9.0 mg/dL (2.00 to 2.25 mmol/L; Fig. 1). Patients
continued taking the dose of rhPTH(1-84) at which their serum calcium levels were stable in the target
range and that permitted the lowest possible doses of oral calcium and calcitriol.
The study was conducted in accordance with applicable International Council for Harmonization
Guidelines, Good Clinical Practice, and the World Medical Association Declaration of Helsinki and its
amendments. The study was approved by central or local institutional review boards, and all patients
provided written informed consent.
Outcome measures
Outcome measures included mean change from baseline in albumin-corrected serum calcium, phosphorus,
and creatinine levels; estimated glomerular filtration rate (eGFR); 24-hour urinary calcium excretion; and
impact of thiazide diuretics on urinary calcium. Other outcome measures included incidence of treatment-
emergent adverse events (AEs) and treatment-emergent serious AEs; mean percentage change from
baseline in oral calcium and calcitriol doses; and mean change from baseline in serum 1,25(OH) D, bone
turnover markers (BTMs), and bone mineral density (BMD). Fractional excretion of calcium (FECa),
urinary calcium adjusted for body weight, and mean Ca × P product were also determined as post hoc
analyses.
The composite efficacy outcome was the proportion of patients who achieved a reduction in the use of oral
calcium supplements (≥50% reduction in dose from baseline or oral calcium dose ≤500 mg/d) and calcitriol
(≥50% reduction in dose from baseline or oral calcitriol dose ≤0.25 µg/d) while normalizing or maintaining
albumin-corrected serum calcium levels compared with the baseline value and not exceeding the ULN for
the central laboratory [10.2 mg/dL (2.55 mmol/L)].
Assessments
On the days of clinic visits, serum for laboratory assessments and measurement of BTMs was collected
before the daily injection of study drug. Albumin-corrected serum calcium, total serum calcium, and serum
phosphorus levels, and Ca × P product were assessed at baseline, week 4, week 8, every 8 weeks up to
week 48, and week 52. Thereafter, total serum calcium and serum phosphorus levels, and Ca × P product
were evaluated every 2 months to month 60, and albumin-corrected serum calcium levels were determined
yearly. The 24-hour urinary calcium and serum creatinine levels, and eGFR were determined at baseline
and at weeks 16, 32, and 52, and then every 4 months to month 60. AEs were assessed at study visits and
also could be reported at any time; serious AEs were recorded within 24 hours of awareness. Serum
1,25[OH] D was measured at baseline, weeks 24 and 52, and every 6 months thereafter. Serum BTMs
[bone-specific alkaline phosphatase (BAP), cross-linked C-telopeptide of type 1 collagen (CTX), and
aminoterminal propeptide of type 1 collagen (P1NP)] were assessed at baseline; at weeks 8, 16, 24, 40, and
52 during the first year of study; then every 4 months to month 60. BMD of the lumbar spine, total hip,
femoral neck, and one-third distal radius was assessed via dual-energy x-ray absorptiometry at baseline and
yearly thereafter.
Calcium and phosphorus levels were measured using commercially available assays (ADVIA ; Siemens
Healthcare Diagnostics, Tarrytown, NY). Inorganic phosphate was measured and expressed as milligrams
per deciliter of phosphorus; the standard conversion factor of 0.323 for inorganic phosphate was used to
generate the data in International System of Units (mmol/L) (22). Concentrations of 1,25[OH] D were
determined by liquid chromatography–tandem mass spectrometry. Albumin-corrected serum calcium level
2
2
®
2
Safety and Efficacy of 5 Years of Treatment With Recombinant Human P... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760337/?report=printable
4 of 26 2/11/2020, 8:45 AM
was determined using the following formula: corrected calcium = serum calcium + 0.8 × (4 – serum
albumin). eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation
(23). FECa was determined using the following formula: FECa = (24-hour urine calcium/serum
calcium)/(24-hour urine creatinine/serum creatinine) (24).
BTM levels were determined using commercially available immunoassays (BAP: LIAISON  BAP
OSTASE  immunoassay, DiaSorin, Stillwater, MN; P1NP: Cobas  total P1NP, Roche Diagnostics,
Indianapolis, IN; and CTX Cobas β-CrossLaps/serum, Roche Diagnostics).
Dual-energy x-ray absorptiometry densitometers were Hologic  (QDR 4500, Delphi, Horizon, or
Discovery models; Hologic, Waltham, MA) or Lunar  (Prodigy or iDXA models; GE Healthcare, Chicago,
IL). Any changes or upgrades to the scanner or software were reviewed before use. Instrument
standardization and calibration were conducted using the Bona Fide Phantom (BioClinica, Doylestown,
PA). Each clinical site was required to scan the Bona Fide Phantom 10 consecutive times and submit for
central analysis.
Statistical analysis
SAS, version 9.2 (SAS Institute Inc., Cary, NC), was used for all statistical procedures. Continuous
variables were summarized by descriptive statistics with the number of patients, mean, and SD; categorical
variables included the number and percentage of patients. Because of the open-label nature of the study and
the lack of comparator, no formal statistical testing or between-group comparisons were conducted. Data
are presented as mean ± SD unless otherwise indicated.
Baseline values were defined as those measured just before initiation of rhPTH(1-84) treatment, whether
that occurred at the start of REPLACE, RELAY (for patients who did not participate in or received placebo
in REPLACE), or RACE (for patients who received placebo in REPLACE and did not participate in
RELAY). End points for oral calcium and calcitriol levels were based on investigator-prescribed data. AEs
were coded using the Medical Dictionary for Regulatory Activities, version 13.0
(https://www.meddra.org/).
Results
Patient disposition and baseline characteristics
Forty-nine patients who completed RELAY and/or REPLACE were enrolled from 12 US centers. The
median interruption between completion of the previous study and initiation of treatment in RACE was 1.0
(interquartile range, 1.0 to 1.0) day. Forty enrolled patients (81.6%) had completed 60 months of
rhPTH(1-84) treatment as of 8 May 2017. Nine patients withdrew from the study for the following reasons:
patient’s decision (n = 5; none were AE-related), investigator’s decision (n = 2), AE (n = 1), or patient
declined to enter the extension after the first 12 months were completed (n = 1). Table 1 summarizes key
patient demographics and baseline characteristics.
Biochemical parameters
Mean albumin-corrected serum calcium concentration was maintained within the target range of 8.0 to 9.0
mg/dL (2.00 to 2.25 mmol/L) compared with baseline [mean, 8.4 ± 0.70 mg/dL (2.1 ± 0.17 mmol/L); n =
49] through month 60 [mean, 8.5±0.78 mg/dL (2.1 ± 0.20 mmol/L); n=40; Fig. 2(a)]. Mean change from
baseline at month 60 was 0.10 ± 0.89 mg/dL (0.02 ± 0.22 mmol/L).
Urinary calcium excretion trended downward over 60 months of rhPTH(1-84) treatment [Fig. 2(b)]. Mean
urinary calcium excretion was above normal at baseline [356.7 ± 200.37 mg/24 hours (8.9±5.01 mmol/24
®
® ®
®
®
®
Safety and Efficacy of 5 Years of Treatment With Recombinant Human P... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760337/?report=printable
5 of 26 2/11/2020, 8:45 AM
hours); n = 48) and declined to a level within the normal range at month 60 [246.3 ± 132.21 mg/24 hours
(6.2 ± 3.31 mmol/24 hours); n = 40). Mean change from baseline at month 60 was −101.2 ± 236.24 mg/24
hours [−2.5 ± 5.91 mmol/24 hours; 95% CI, –176.78 to –25.67 mg/24 hours (95% CI, –4.42 to –0.64
mmol/24 hours)]. Data are reported for men and women separately in Fig. 2(b). At baseline, 33 of 48
patients (68.8%) had hypercalciuria, compared with 18 of 40 patients (45.0%) at month 60. Furthermore,
mean FECa was 3.1% ± 1.18% at baseline (n = 47) and decreased to 2.2% ± 1.22% at month 60 (n = 40),
representing a change from baseline of –18.1% ± 47.06% (95% CI, –33.3% to –2.8%; n = 39). Mean
urinary calcium normalized to body weight also declined, from 4.3 ± 2.44 mg/24 hour/kg (0.11 ± 0.061
mmol/24 hour/kg) at baseline (n = 48) to 3.0 ± 1.80 mg/24 hour/kg (0.07 ± 0.045 mmol/24 hour/kg) at
month 60 [n = 40; mean change from baseline, –1.1 ± 2.62 mg/24 hour/kg (–0.03 ± 0.066 mmol/24
hour/kg)]. The mean decrease in urinary calcium was greater in the subgroup of patients who were using
thiazide diuretics (n = 10) at month 60 [−177.5 ± 239.55 mg/24 hours (−4.4 ± 5.99 mmol/24 hours); 95%
CI, –348.9 to –6.1 mg/24 hours (95% CI, –8.72 to –0.15 mmol/24 hours)]; however, patients who were not
receiving thiazides (n = 39) also had a decrease in urinary calcium [−75.8 ± 233.59 mg/24 hours (−1.9 ±
5.84 mmol/24 hours); 95% CI, –163.0 to 11.4 mg/24 hours (95% CI, –4.1 to 0.3 mmol/24 hours); n = 30].
Serum phosphorus levels were uniformly lower than baseline throughout the 60 months of rhPTH(1-84)
treatment [Fig. 2(c)]. Mean serum phosphorus concentration was 4.8 ± 0.58 mg/dL (1.56 ± 0.188 mmol/L)
at baseline (n = 49) and 3.9 ± 0.66 mg/dL (1.27 ± 0.213 mmol/L) at month 60 (n = 40), with a mean change
from baseline of ‒1.0 ± 0.78 mg/dL (‒0.31 ± 0.253 mmol/L). At baseline, 26 patients had serum
phosphorus levels above the normal range [i.e., >4.5 mg/dL (>1.45 mmol/L)] compared with only eight
patients at month 60.
Mean Ca × P product was 42.1 ± 6.35 mg /dL  (3.4 ± 0.51 mmol /L ; n = 49) at baseline and 34.2 ± 5.55
mg /dL  (2.8 ± 0.45 mmol /L ; n = 40) at month 60. The mean change from baseline was −8.5 ± 8.29
mg /dL  [−0.7 ± 0.67 mmol /L ; Fig. 2(d)].
Renal function
Mean serum creatinine levels were stable with treatment over the 5 years [baseline, 0.96 ± 0.205 mg/dL
(84.7 ± 18.16 µmol/L), n = 49; month 60, 0.93 ± 0.22 mg/dL (81.7 ± 19.85 µmol/L), n = 40; mean change
from baseline, −0.06 ± 0.15 mg/dL (−4.9 ± 13.02 µmol/L)] and remained within the reference range
throughout the study [Fig. 3(a)]. Mean eGFR by the Chronic Kidney Disease Epidemiology Collaboration
equation was also stable: 77.7 ± 17.67 mL/min/1.73 m  (n = 49) at baseline and 78.0 ± 18.80 mL/min/1.73
m  (n = 40) at month 60 [mean change from baseline, 2.3 ± 11.81 mL/min/1.73 m ; n = 40; Fig. 3(b)]. A
similar eGFR profile was obtained when the prespecified Cockcroft-Gault formula was used to generate the
data (data not shown).
Adverse events
No clinically significant changes in vital signs, physical examinations, or ECG parameters were observed
over the treatment period. In addition, there were no clinically meaningful trends in safety laboratory
results beyond those already discussed. Treatment-emergent AEs were reported in 48 of 49 patients
(98.0%) while they were receiving rhPTH(1-84) treatment (Table 2). Five injection site reactions were
reported in four patients (8.2%); all were mild. Severe AEs were reported in 17 patients (34.7%). AEs
assessed by the investigator as related to treatment with rhPTH(1-84) were reported in 25 patients (51.0%).
The most common AEs considered to be related to treatment were nausea (n = 7; 14.3%), hypercalcemia (n
= 6; 12.2%), hypocalcemia (n = 4; 8.2%), tetany (n = 4; 8.2%), constipation (n = 3; 6.1%), and paresthesia
(n = 3; 6.1%).
Serious AEs occurred in 13 of 49 patients (26.5%), and none was considered by the investigator to be
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related to treatment with rhPTH(1-84). No cases of bone tumors or osteosarcoma were reported. One death
was reported during the study. A 52-year-old woman died of acute systolic congestive heart failure thought
to be related to her comorbidities (including hypertension, hyperlipidemia, and cardiomyopathy) and to be
unrelated to rhPTH(1-84) treatment.
rhPTH(1-84) and oral supplement dosing and serum 1,25(OH) D level
At the start of RACE, the dose of rhPTH(1-84) was 25 µg/d for 4.1% of patients (n = 2), 50 µg/d for 93.9%
(n = 46), and 100 µg/d for 2.0% (n = 1; Fig. 4). At month 60, the rhPTH(1-84) dose was 100 µg/d for
72.5% of patients (n = 29), 75 µg/d for 10.0% (n = 4), and 50 µg/d for 17.5% (n = 7). Treatment with
rhPTH(1-84) led to reductions in daily doses of oral calcium and calcitriol that were sustained throughout
the 5-year treatment period (Fig. 5). At month 60, daily intake of supplemental oral calcium and calcitriol
had declined by a mean of 53.4% ± 81.34% (95% CI, –79.4% to –27.4%) and 75.7% ± 38.44% (95% CI,
–88.0% to –63.5%), respectively, from baseline. Furthermore, at month 60, 26.5% of patients (n = 13) had
stopped taking oral calcium, 55.1% (n = 27) had stopped oral calcitriol, and 18.4% (n = 9) had stopped
both. Despite reductions in supplementation with oral calcitriol, serum concentrations of 1,25[OH] D
increased by a mean of 9.1 ± 11.72 pg/mL (95% CI, 4.3 to 14.0 pg/mL; n = 25) between baseline (30.6 ±
12.21 pg/mL; n = 29) and month 60 (39.4 ± 12.66 pg/mL; n = 39).
Composite efficacy outcome
The composite efficacy outcome was achieved by 70.0% (95% CI, 53.5% to 83.4%; n = 28) of patients at
month 60 (Fig. 6). Twenty-one of these patients (75.0%) received the maximum dose (100 µg/d) of
rhPTH(1-84), two (7.1%) received 75 µg/d, and five (17.9%) received 50 µg/d. Of the 12 patients who did
not achieve the efficacy end point, eight (66.7%) received the maximum dose, two (16.7%) received 75
µg/d, and two (16.7%) received 50 µg/d. Thus, four patients did not achieve the efficacy end point but
received less than the maximum dose of rhPTH(1-84).
Bone turnover and BMD
Mean serum concentrations of all BTMs increased from baseline with rhPTH(1-84) treatment, reaching a
plateau 6 to 16 months after initiation of treatment, then declining and remaining within normal limits for
CTX and BAP, and slightly above the normal limit for P1NP (Fig. 7). Baseline, maximum, and month 60
values for BTMs are reported in Table 3. Total serum alkaline phosphatase levels, measured as part of
routine safety laboratory screening, responded similarly to BAP over the course of the study (data not
shown).
At baseline, mean BMD Z-scores at lumbar spine, total hip, and femoral neck were greater than the normal
range for age, sex, and race and were particularly high at the lumbar spine (Table 4). After 60 months of
rhPTH(1-84) treatment, the mean BMD Z-score at the distal one-third radius site was reduced compared
with baseline. At other sites, mean Z-scores remained stable and above 1 between baseline and month 60.
Discussion
Findings from 5 years of treatment with rhPTH(1-84) in the RACE study provide further evidence
supporting the long-term safety and efficacy of rhPTH(1-84) in the treatment of adults with
hypoparathyroidism. Along with overall reductions in oral supplementation, mean albumin-corrected serum
calcium levels were maintained within the target range over 60 months of treatment, suggesting sustained
long-term efficacy. Importantly, mean 24-hour urine calcium declined to levels within the normal range,
and mean FECa showed an 18% decrease between baseline and 60 months, indicating that renal tubular
reabsorption of calcium improved with rhPTH(1-84). Similar beneficial effects on urinary calcium
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excretion were seen in the only other long-term open-label study of rhPTH(1-84), the single-center HEXT
(Hypo-Extended: Effect of PTH on Skeleton in Hypoparathyroidism) Study (16, 18). Interestingly,
although mean 24-hour urine calcium levels declined, but remained above the ULN for women in the
shorter 6-month REPLACE study, the mean urine calcium level continued to decline in this long-term
study into the normal range for men and women (urinary calcium decreased by 73.6 mg/24 hours by week
24 in REPLACE compared with a decrease of 101.2 mg/24 hours by month 60 in RACE) (17). This may
indicate that longer treatment may be necessary for normalization of urine calcium levels.
RACE provides additional evidence that treatment with rhPTH(1-84) improves other aspects of mineral
and skeletal homeostasis. The decrease in serum phosphorus level was similar to that reported from the
long-term HEXT study (18). Reductions in serum phosphorus with rhPTH(1-84) treatment likely drove the
observed declines in Ca × P product concentrations, which were maintained throughout the study. In
addition, kidney function was preserved; serum creatinine remained within the normal range, and eGFR
was stable over 5 years in RACE.
BTMs, which are low in patients with hypoparathyroidism, increased from baseline and peaked at around 1
year after the initiation of rhPTH(1-84) treatment, then declined but remained above pretreatment values
through year 5. Similar trends in the pattern of BTMs have been reported in the HEXT study (16, 18) but
with differences in the magnitude of increase and time course of change that may be due to differing
treatment regimens. The findings from these studies suggest the initial large increase in BTMs with
rhPTH(1-84) treatment is temporary (18, 25) and is followed by a new steady state of more normal bone
turnover with continued therapy. Changes in calcium and phosphorus flux from bone may at least partially
explain the trend for increases in calcium supplements later in the treatment period, but this was not tested
directly in this study.
BMD is often elevated in patients with longstanding hypoparathyroidism (26). In this study, no meaningful
changes in BMD Z-scores were observed at the lumbar spine, hip (total), and hip (femoral neck), whereas a
decrease in Z-score occurred at the distal one-third radius. These results are similar to trends seen in the
HEXT trial at 6 years of follow-up (18) and are not unexpected given the differential effects of PTH on
cortical and trabecular bone (27–29). Longer observations will be necessary to obtain more insights into the
changes in bone density and bone quality during treatment with rhPTH(1-84).
One patient discontinued this 5-year study because of an AE, which was not considered related to
treatment. The AE profile of rhPTH(1-84) was similar to that observed in the 24-week REPLACE (17) and
8-week RELAY (20) studies. The most commonly reported AEs were related to the underlying disease
(e.g., hypocalcemia, muscle spasms, paresthesia, nephrolithiasis) and common ailments (e.g., sinusitis,
nausea).
Limitations of RACE include the open-label design, the lack of a control arm, and insufficient power to
perform statistical analyses. Of the 12 patients who did not achieve the three-part efficacy end point in
RACE, four did not receive the maximum dose of rhPTH(1-84) of 100 µg/d. Therefore, these patients may
have been undertreated. The impact of rhPTH(1-84) on health-related quality of life in adults with
hypoparathyroidism was not captured in RACE. The interpretation of BMD data reported here is limited by
the small sample size and the use of different densitometers with lack of standardization and cross-
calibration.
Continued use of rhPTH(1-84) throughout 5 years resulted in a safety profile that was consistent with other
studies; no new safety findings were identified (17, 20). Sustained improvements in mineral homeostasis
and increases in BTMs were observed. Treatment with rhPTH(1-84) allowed major reductions in oral
calcium supplements and active vitamin D analogs while maintaining albumin-corrected serum calcium
concentration within the target range. Importantly, over the 5 years of treatment, eGFR and serum
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creatinine levels remained stable, mean urinary calcium excretion normalized, and serum phosphorus and
Ca × P product levels improved.
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Figure 1.
Study design. Dotted lines indicate that treatment interruptions could have occurred between studies. Baseline values were
those measured just before initiation of rhPTH(1-84) treatment, whether that occurred at the start of REPLACE, RELAY,
or RACE. BL, baseline; *Current analysis; †end of study.
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Table 1.
Patient Demographics and Baseline Characteristics
Characteristic
No. of patients 49
Age, mean (SD), y 48.1 (9.78)
Female sex 40 (81.6)
Race
 White 46 (93.9)
 Asian 2 (4.1)
 Native Hawaiian/Pacific Islander 1 (2.0)
Duration of hypoparathyroidism, mean (SD), y 15.9 (12.49)
Prescribed calcitriol at baseline, µg/d
 Mean (SD) 0.67 (0.446)
 ≤0.25 13 (26.5)
 >0.25−0.50 16 (32.7)
 >0.50 20 (40.8)
Prescribed oral calcium at baseline, mg/d
 Mean (SD) 2194 (1732.3)
 0−2000 31 (63.3)
 >2000 18 (36.7)
Data are given as no. (%) unless otherwise indicated.
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Figure 2.
Open in a separate window
Changes in (a) albumin-corrected serum calcium level, (b) urinary calcium excretion, (c) serum phosphorus level, and (d)
Ca × P product over time.
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Figure 3.
Changes in (a) serum creatinine and (b) eGFR over time.
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Table 2.
Treatment-Emergent AEs Reported in ≥10% of Patients
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AE Severity, No. (%)
Preferred Term Mild Moderate Severe All AEs (N = 49)
Hypocalcemia 8 (16.3) 10 (20.4) 0 18 (36.7)
Muscle spasms 6 (12.2) 9 (18.4) 1 (2.0) 16 (32.7)
Nausea 10 (20.4) 5 (10.2) 0 15 (30.6)
Paresthesia 12 (24.5) 3 (6.1) 0 15 (30.6)
Sinusitis 5 (10.2) 9 (18.4) 1 (2.0) 15 (30.6)
Headache 4 (8.2) 7 (14.3) 1 (2.0) 12 (24.5)
Arthralgia 1 (2.0) 9 (18.4) 2 (4.1) 12 (24.5)
Bronchitis 6 (12.2) 5 (10.2) 0 11 (22.4)
Nasopharyngitis 6 (12.2) 4 (8.2) 0 10 (20.4)
Back pain 2 (4.1) 6 (12.2) 2 (4.1) 10 (20.4)
Constipation 7 (14.3) 2 (4.1) 1 (2.0) 10 (20.4)
Diarrhea 5 (10.2) 4 (8.2) 0 9 (18.4)
Extremity pain 4 (8.2) 5 (10.2) 0 9 (18.4)
Urinary tract infection 5 (10.2) 3 (6.1) 1 (2.0) 9 (18.4)
Fatigue 2 (4.1) 4 (8.2) 2 (4.1) 8 (16.3)
Influenza 4 (8.2) 4 (8.2) 0 8 (16.3)
Vitamin D deficiency 6 (12.2) 2 (4.1) 0 8 (16.3)
Viral gastroenteritis 2 (4.1) 6 (12.2) 0 8 (16.3)
Hypercalcemia 4 (8.2) 3 (6.1) 0 7 (14.3)
Tetany 2 (4.1) 5 (10.2) 0 7 (14.3)
Upper respiratory tract infection 5 (10.2) 2 (4.1) 0 7 (14.3)
Anxiety 1 (2.0) 6 (12.2) 0 7 (14.3)
Joint sprain 3 (6.1) 3 (6.1) 1 (2.0) 7 (14.3)
Nephrolithiasis 3 (6.1) 2 (4.1) 1 (2.0) 6 (12.2)
Decreased blood calcium 5 (10.2) 1 (2.0) 0 6 (12.2)
Dizziness 5 (10.2) 1 (2.0) 0 6 (12.2)
Vomiting 4 (8.2) 2 (4.1) 0 6 (12.2)
Chest discomfort 4 (8.2) 2 (4.1) 0 6 (12.2)
Hypertension 2 (4.1) 4 (8.2) 0 6 (12.2)
Urine calcium increased 4 (8.2) 1 (2.0) 0 5 (10.2)
Myalgia 1 (2.0) 4 (8.2) 0 5 (10.2)
Dyspepsia 2 (4.1) 3 (6.1) 0 5 (10.2)
Abdominal pain 3 (6.1) 1 (2.0) 1 (2.0) 5 (10.2)
Insomnia 5 (10.2) 0 0 5 (10.2)
Muscle strain 1 (2.0) 4 (8.2) 0 5 (10.2)
Palpitations 5 (10.2) 0 0 5 (10.2)
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AE Severity, No. (%)
Preferred Term Mild Moderate Severe All AEs (N = 49)
Vitamin D decreased 3 (6.1) 2 (4.1) 0 5 (10.2)
Open in a separate window
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Figure 4.
Open in a separate window
Changes in rhPTH(1-84) dosing from the starting dose for the first study visit of RACE through month 60.
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Figure 5.
Percentage change from baseline in dose of oral calcium and calcitriol over time.
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Figure 6.
Percentage of patients who achieved the composite efficacy end point over time.
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Figure 7.
Open in a separate window
Change in serum (a) CTX, (b) BAP, and (c) P1NP BTMs over time.
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Table 3.
Changes in Bone Turnover Markers
BTM Baseline (N = 49) Maximum Value (n = 47) Month 60 (n = 38)
CTX, ng/L (normal, ≤690 ng/L) 213.0 (172.34) 699.1 (469.5) 463.7 (388.30)
BAP, μg/L (normal, 6–30 µg/L) 9.6 (3.32) 20.7 (12.18) 17.8 (13.82)
P1NP, μg/L (normal, 20–108 µg/L) 33.7 (19.72) 201.5 (160.72) 144.1 (153.73)
Data reported as mean (SD).
Maximum value occurred at week 40 for CTX, month 12 for P1NP, and month 16 for BAP.
n = 48.
n = 37.
n = 45.
n = 46.
a
b c
b d c
e
a
b
c
d
e
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Table 4.
BMD Z-Score at Baseline and Month 60
Baseline Month 60
Location Mean (SD) No. Mean (SD) No.
Lumbar spine 2.1 (1.47) 40 2.1 (1.52) 35
Hip, total 1.6 (1.12) 40 1.5 (1.09) 34
Hip, femoral neck 1.4 (1.24) 40 1.4 (1.27) 34
Distal one-third radius 0.9 (0.83) 40 0.5 (1.19) 35
Excludes results from six patients who were assessed by different dual-energy x-ray absorptiometry machines at
baseline vs month 60 (Hologic and GE Lunar instruments, respectively).
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